Oncology Institute of Southern Switzerland
23
9
10
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
21.7%
5 terminated/withdrawn out of 23 trials
54.5%
-32.0% vs industry average
4%
1 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (23)
Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer
Role: collaborator
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Role: collaborator
Effect of a Music Intervention in Reducing Distress and Pain in Patients With Lung Cancer Undergoing Mini-invasive Surgery
Role: lead
Lifestyle Intervention in Patients With Metastatic Prostate Cancer
Role: lead
Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients
Role: lead
Early Detection of Cardiotoxicity From Systemic and Radiation Therapy in Breast Cancer Patients
Role: lead
Personalized Risk Stratification Model of Follicular Lymphoma Patients
Role: lead
Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia
Role: lead
The Immune Landscape of Epithelial Ovarian Cancer
Role: lead
Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer
Role: lead
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Role: lead
Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells
Role: lead
Metronidazole as Preoperative Therapy in CRC / FusoMetro-001
Role: lead
Tumor Molecular Profiling in Early Phase Clinical Trials
Role: lead
Hypofractionated Brain Radiationcavity
Role: lead
Liquid Biopsy in Mature B-cell Tumors
Role: lead
Prevalence of Wild Type ATTR
Role: lead
Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
Role: collaborator
Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19
Role: collaborator
Jalosome® Soothing Gel Efficacy Grade 2 or 3 Radiodermatitis.
Role: collaborator